Compare Citius Pharmaceuticals Inc (CTXR) vs Equinix Inc (EQIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Equinix Inc — how do they compare? Citius Pharmaceuticals Inc trades at $0.54 (market cap $14.64M), while Equinix Inc trades at $1,014.28 (market cap $100.95B). The key difference: Equinix Inc is far larger — about 6895.5× Citius Pharmaceuticals Inc's market cap, and Equinix Inc pays a 1.92% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | EQIX | |
|---|---|---|
Market Cap | $14.64M | $100.95B |
Sector | Health | Real Estate |
52-Week High | $1.82 | $1.12K |
52-Week Low | $0.53 | $726.09 |
Enterprise Value | $10.86M | $121.23B |
Dividend Yield | — | 1.92% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
EQIX trades at $1,039.53, down 1.11% on the day, with a bullish technical signal and strong analyst support (74.51% buy ratings). Revenue grew to $9.22B in 2025, with net income reaching $1.35B, though recent quarters showed mixed earnings results. The company benefits from AI infrastructure demand, evidenced by partnerships with Cisco and NVIDIA (Business Wire, 2026-06-17).
Outlook remains positive due to recurring revenue growth and AI tailwinds, but high valuation (P/E 71.89) and negative cash flow (-$1.26B in 2025) pose risks. Debt levels are rising, with debt-to-asset ratio at 47.13% in 2025. The consensus price target of $1,110 suggests upside potential if execution aligns with AI-driven demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Equinix Inc
Equinix is a retail provider of data centers, enabling hundreds of enterprise tenants to house their servers and networking equipment in a collocated environment. Tenants can then connect with each other, through cloud service providers and telecom networks. Equinix operates 240 data centers in 66 markets worldwide and owns just less than half of them. The firm has roughly 10,000 customers, including 2,000 networks, that are dispersed over five verticals: Cloud and IT Services, Content Providers, Network and Mobile Services, Financial Services, and Enterprise. About 70% of Equinix's revenue comes from renting space to tenants and related services, and more than 15% comes from connecting customers with each other. Equinix operates as a real estate investment trust.
Read more on EQIX →
